Showing results (1-10 of 30) with videos related to
Sort By:
Pageof 3
Nature Reviews. Drug Discovery|March 2, 2011
Advances in the preclinical testing of cancer therapeutic hypothesesGiordano Caponigro, William R SellersJournal of Biotechnology|August 2, 2003
Functional analysis of expressed peptides that bind yeast STE proteinsGiordano Caponigro, Majid Abedi, Alexander KambYeast (Chichester, England)|January 5, 2002
Expression levels of transdominant peptides and proteins in Saccharomyces cerevisiaeTanya Sandrock, Mark Poritz, Marianne Kim, et al.Molecular Cancer Research : MCR|April 12, 2008
Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell deathWinfried Elis, Ellen Triantafellow, Natalie M Wolters, et al.Oncotarget|February 21, 2020
Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFRHengyu Lu, Chen Liu, Hung Huynh, et al.Cell Cycle (Georgetown, Tex.)|January 30, 2009
Single-vector inducible lentiviral RNAi system for oncology target validationDmitri Wiederschain, Susan Wee, Lin Chen, et al.Molecular Cancer Research : MCR|June 29, 2017
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic ActivityCaroline M Emery, Kelli-Ann Monaco, Ping Wang, et al.Molecular Cancer Therapeutics|May 10, 2019
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK InhibitorsHengyu Lu, Chen Liu, Roberto Velazquez, et al.Oncotarget|November 17, 2018
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer modelsSunkyu Kim, Ralph Tiedt, Alice Loo, et al.Oncotarget|April 16, 2020
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer modelsSunkyu Kim, Ralph Tiedt, Alice Loo, et al.Pageof 3